- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jarushka Naidoo Discusses Evolution of Biomarker Testing
Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MB BCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MBBCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Transcript
There are several potential biomarkers that have emerged in recent years, but in what areas and for what treatments are biomarkers still urgently needed to guide treatment decisions?
I think there are tumor types that are rarer, in which biomarker testing is still in its infancy. So, for those tumor types, I think there is still a way to go. Also, there are tumor types that appear to respond better to combinations, and we’re in an era of giving combinations, either with other immunotherapy agents or with chemotherapy.
So, I think biomarker testing is going to evolve to not just look at checkpoint inhibitor monotherapy, but also to look at combinations. And the biomarkers may be different depending on what treatment we give.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
